Innovation
Innovation is central to GALSER’s vision for clinical research. We continuously explore new methodologies, technologies, and collaborations to enhance the efficiency, quality, and impact of clinical trials. By proactively adapting to emerging trends, we position ourselves, and our clients, for future success.
Novel Clinical Trials
GALSER embraces novel clinical trial designs, such as Decentralized Clinical Trials (DCTs) and Adaptive Trial Designs, to optimize trial efficiency and enhance patient-centricity.
Decentralized Clinical Trials leverage digital technologies to facilitate remote participation, significantly improving patient accessibility, recruitment, and retention. By enabling data collection directly from patients’ homes, DCTs optimize processes and enhance patient comfort.
Adaptive Trial Designs allow modifications based on interim data analyses, enabling faster decision-making, more efficient resource allocation, and potentially shorter trial durations. This flexibility not only improves the trial’s efficiency but also supports ethical considerations by minimizing unnecessary patient exposure.
Furthermore, GALSER actively integrates advanced technological tools-such as digital health solutions, clinical trial management software, and artificial intelligence (AI), to improve operational effectiveness, data accuracy, and strategic insights during several phases of the trial management and execution.
Strategic Partnerships
At GALSER, we firmly believe innovation thrives through collaboration. We maintain strong partnerships with academic institutions, specialized research centers, and leading technology providers. These collaborations facilitate the integration of innovative and advanced technologies into our clinical trial operations, continually elevating our methodological capabilities.
We also actively engage with patient associations to align our research approaches with patient perspectives and needs. Such interactions strengthen trial designs that reflect real-world experiences, improving both participation rates and clinical outcomes.
Start-up Program
Recognizing the unique challenges faced by biotech and pharmaceutical start-ups, GALSER provides specialized support through our dedicated Start-Up Program. We assist young companies transitioning from preclinical development into clinical phases, guiding them through Swiss regulatory pathways and facilitating efficient initiation of clinical trials.
Through our expertise, extensive local network, and direct access to Switzerland’s exceptional research infrastructure, start-ups benefit from efficient, high-quality trial execution. This tailored support accelerates their innovation journey and enhances the likelihood of clinical and commercial success.
FAQ
